Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05327114 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Phase 2 study of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
- 20
- Study locations
NCT05327114: Recruiting Phase 2 study of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, sponsored by Janssen Research & Development.
NCT05327114 is a Phase 2 study of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 201 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05327114, a Phase 2 study of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
Primary Outcome
Stage B time to first occurrence of a relapse event will be reported.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nipocalimab
Study Locations (20)
Other
- Hospital Italiano de Buenos Aires - Buenos Aires
- Hospital Gral Agudos Ignacio Pirovano - Buenos Aires
- The Alfred Hospital - Melbourne
- Gold Coast University Hospital - Parkwood
- Peking University First Hospital - Beijing
- Xuanwu Hospital ,Capital Medical University - Beijing
- Beijing Tiantan Hospital, Capital Medical University - Beijing
Florida
- Healthcare Innovations Institute Inc - Coral Springs
- Neurology Associates PA - Maitland
New York
- The Neurological Institute of New York - New York
- South Shore Neurologic Associates - Patchogue - Patchogue
Colorado
- IMMUNOe Health and Research Centers - Centennial
Kansas
- University of Kansas Medical Center - Kansas City
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Boston Clinical Trials - Boston
Michigan
- Beaumont Hospital Royal Oak - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2022-09-23 |
| Est. Completion | 2028-07-11 |
| Phase | Phase 2 |
What NCT05327114 shows while recruiting
NCT05327114 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% higher).
The record links to 1 condition, with Polyradiculoneuropathy, Chronic Inflammatory Demyelinating appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05327114 names 20 study sites across 12 states, led by Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05327114 about?
NCT05327114 is a clinical study titled "Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)". The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
What is the current status of trial NCT05327114?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2022-09-23. Estimated completion is 2028-07-11.
What conditions does trial NCT05327114 study?
This clinical trial studies the following conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating.
What interventions are being tested in trial NCT05327114?
The interventions under investigation include: Placebo (DRUG), Nipocalimab (DRUG).
Who is sponsoring clinical trial NCT05327114?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05327114 being conducted?
This trial has 20 study locations across Colorado, Florida, Kansas, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05327114's enrollment target sits among peer trials
201 302nd of 2000 higher than 1,697 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
- NCT06945419 · 201 participants · Phase 1
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI